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Immunohistochemical distribution and quantification of crystal matrix
protein. The aim of this study was to determine the immunohistochem-
ical distribution and quantification of crystal matrix protein (CMP).
CMP, a 31 kDa glycoprotein, is the principal macromolecule found in
calcium oxalate crystals generated in human urine, and is a potent
inhibitor of crystal aggregation. A polyclonal rabbit anti-human CMP
antibody was used to examine renal tissue by immunohistochemical
techniques and light microscopy (N = 45). Twenty-five other human
organs were similarly assessed. Quantification was performed using a
visual analogue scale. CMP was visible as cytoplasmic staining in the
epithelial cells of the TALH and the distal convoluted tubule including
the macula densa in a subgroup of nephrons. CMP was not identified
elsewhere in the urinary tract or in the extrarenal organs examined.
Despite a trend indicating that the kidneys of normal men had more
CMP than those of normal women, the difference failed to reach
significance (P = 0.11). There was, however, more CMP in the stone
formers group compared with either normal men (P < 0.01) or normal
women (P < 0.01). This protein may be an important determinant of
calcium oxalate kidney stone disease.
Throughout all kidney stones there exists a latticework of
organic material commonly referred to as the matrix [1]. Its
importance in the pathogenesis of stone disease must not be
overlooked, for it may hold the key that will allow us to
manipulate the natural history of this condition in the future.
More than 70% of urinary calculi contain calcium oxalate
(CaOx) as their principal component [21, and in these stones the
matrix constitutes approximately 2.5% of the stone's dry weight
and is distributed throughout the entire structure [3—5].
Chemical analysis of stone matrix has proved difficult be-
cause of its poor solubility [6], and the fact that its dissolution
and extraction prior to analysis necessitates the use of aggres-
sive procedures, such as acid hydrolysis, which may them-
selves alter its chemical structure. Furthermore, stones take
varying periods to grow before becoming clinically apparent,
and are often stored for years prior to analysis [7]. As a result,
consequent chemical cross-linking and degeneration of proteins
may alter the final composition of matrix so that it bears little
resemblance to that prevailing when the core of the stone was
initially formed. If this were not enough to undermine the
validity of analytical findings, the matter is further complicated
by the fact that organic material in the stone's crystalline
structure may derive from two distinct sources, namely constit-
uents normally present in urine and those liberated variably
from the epithelial lining or the interstitium of the urinary tract
as a consequence of trauma induced by the enlarging stone [8].
Thus, recent attention has turned to the extraction and
analysis of organic matrix from the precursors of stones, CaOx
crystals, freshly precipitated from whole urine [8, 9]. Since
these crystals are grown in the absence of substances that could
be termed opportunistic contaminants of the growing stone's
matrix, their organic matrix should be representative of normal
urinary macromolecules associated with CaOx crystal forma-
tion in stone pathogenesis.
In an extension of the study by Morse and Resnick [9] we
have analyzed the protein content of CaOx crystals harvested in
this manner and have isolated a urinary protein not previously
described. This has been named crystal matrix protein (CMP),
a 31 kDa glycoprotein [8]. Unpublished studies from our
laboratory have shown that it is a potent inhibitor of calcium
oxalate crystal aggregation, and is present in CaOx crystals in
quantities far in excess of those expected from its concentration
in urine. This lends support to the findings of Morse and
Resnick [9] that the incorporation of urinary proteins into CaOx
crystals is a highly selective phenomenon.
The anatomical origin of CMP is unknown. Doyle, Ryall and
Marshall [8] did not detect CMP in human serum, indicating
that it may be produced and secreted within the urinary tract.
Since this protein may be important in the control of stone
pathogenesis, and perhaps even have a role in renal physiology
and homeostasis, the aims of this study were: (1) to delineate
the distribution of CMP within the human urinary tract; (2) to
investigate its presence in other human tissues; and, (3) to
assess histologically the quantity of CMP in men, women, and
CaOx stone formers.
Methods
Preparation of CMP antibody
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Ten milliliters were bled from each of three New Zealand
white rabbits. Pre-immune serum was prepared and stored at
—70°C, prior to being treated in a similar way to the immune
serum as detailed below.
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Fig. 1. Nine to 18% gradient sodium dodecyl
sulphate polyacrylamide gel electrophoresis
(SDS-PAGE) of human urine (centrd'uged 5000
rpm for 5 mm and passed through a 0.2 im
filter) (lane 1), crystal matrix extract (lane 2), and
human serum (lane 3), all stained with silver.
Alongside is the associated Western blot of the
same samples (lanes I to 3) using anti-human
crystal matrix protein antibody (1:1000), detected
with anti-rabbit antibody conjugated with
peroxidase (1:1000) and stained with
diaminobenzidine in the presence of 0.2% H202.
Despite the many proteins in urine only a few are
incorporated in CaOx crystals, the most
prominent being at 31 kDa, called crystal matrix
protein (CMP). On the Western blot, CMP is
detected in urine and in the crystal matrix
extract, and is absent from serum.
CMP was isolated from urine collected over a 48 hour period
from four healthy volunteers, aged between 19 and 42 years,
and processed as described by Doyle et at [8]. Briefly, crystal-
lization was induced in the pooled urine by the addition of an
oxalate load. The crystals were isolated, washed briefly in
water and 0.1 Mlliter sodium hydroxide and demineralised in
0.25 M/liter EDTA at pH 8.0. The extract was electrodialyzed
over seven days and then passed through a 0.22 im Millipore
filter, before being lyophilized. Since this crystal matrix extract
consisted principally of CMP [8], as shown by sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) [101,
the extract was used without further purification.
Three hundred micrograms of the crystal extract were dis-
solved in 3 ml of water and emulsified with an equal volume of
Freund's complete adjuvant (Difco Laboratories, Detroit,
Michigan, USA). Each of three New Zealand white rabbits was
injected subcutaneously at 20 sites along the back with 0.1 ml
aliquots of the CME adjuvant. At days 14 and 77 the immuni-
zations were boosted with the same inoculum except that
Freund's incomplete adjuvant was substituted for Freund's
complete adjuvant (Difco Laboratories). The rabbits were ex-
sanguinated on day 87, yielding 65 ml of blood.
The antiserum was preabsorbed once with human serum
immunoabsorbent as described by Avrameus and Ternynck [11]
to reduce nonspecific staining. The specificity of this antiserum
was assessed by its use as a primary antibody in the immuno-
chemical staining of Western blots [121 of proteins [including
Tamm-Horsfall glycoprotein (THG)] separated by 9 to 18%
gradient SDS-PAGE (Mini-Protean II apparatus, Bio-Rad Lab-
oratories, Richmond, California, USA) from human urine,
prepared by centrifugation at 5000 rpm (J-21B Beckman®,
USA) for five minutes, then passed through a 0.2 m filter
(Millipore Corporation, Bedford, Massachusetts, USA) and
lyophylized. Venous blood was drawn from a normal volunteer
into a plain tube and allowed to congeal at 22°C for two hours
then centrifuged at 2000 rpm for five minutes (Labofuge M,
Heraeus-Christ GmbH, Germany), and the serum harvested.
Proteins of interest were transferred to nitrocellulose (Amer-
sham International, Buckinghamshire HP79LL, UK) using the
Mini-Protean II apparatus (Bio-Rad Laboratories) and CMP
was detected with anti-rabbit antibody conjugated with perox-
idase (Bio-Rad Laboratories) (1:1000) and stained with diami-
nobenzidine (Sigma Chemical Company, St Louis, Missouri,
USA) in the presence of 0.2% H202 (Western blots) (Fig. 1).
Anti-epithelial membrane antigen antibody
Goat anti-human epithelial membrane antigen (EMA) mono-
clonal antibody was obtained from DAKOPATTS (DK-2600
Glostrup, Denmark). It was diluted 1:1000 in normal horse
serum (DAKOPATTS) prior to use.
Tissue
Fresh human kidney was obtained from 10 nephrectomy
specimens removed because of renal cell carcinoma (7) or
transitional cell carcinoma of the renal pelvis (3). There were
seven males and three females, median age 74, range 57 to 86
years. Macroscopically normal tissue was sampled away from
the site of known pathology and subsequently shown by light
microscopy to be within normal morphological limits. Each
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(1) Tissue blocks not more than 3 mm thick were embedded in
cryomoulds containing OCT Compound (Miles Laborato-
ries), quenched in an isopentane bath cooled in liquid
nitrogen, and stored at —70°C.
(2) Tissue blocks approximately 5 mm thick were placed in
Zamboni's solution [13] for 16 to 24 hours, washed three
times in dimethylsulphoxide, washed three times in phos-
phate buffered saline (PBS) at pH 7.0, transferred to PBS
containing 30% sucrose and 0.2% sodium azide, and stored
at 4°C. Tissue was embedded in OCT Compound and frozen
at —20°C prior to sectioning.
(3) Tissue blocks, not more than 5 mm thick, were fixed in 10%
buffered formalin (pH 7.4) for 12 to 24 hours and embedded
routinely in paraffin wax.
(4) Blocks similar to those in (3) above were fixed in 2.5%
glutaraldehyde for 2 to 24 hours and then embedded in
paraffin wax.
Archival renal tissue (formalin-fixed paraffin-embedded) was
obtained from the routine tissue blocks of kidney specimens
from 35 individuals, stored in the Histopathology Department.
Nephrectomy had been performed in patients for parenchymal
carcinoma (19), transitional cell carcinoma (9), infection (3),
trauma (1), renal arterio-venous malformation (1), renal onco-
cytoma (1), and partial nephrectomy for renal calculi (1),
between 1986 and 1992 at the Flinders Medical Centre (FMC).
The median age of these patients was 63, range 16 to 86 years,
and 24 of them were men. Included in these groups were five
patients known to have had one or more CaOx renal stones who
had their renal surgery because of renal cell carcinoma (1), renal
leiomyoma (1), partial nephrectomy for renal calculi (1), renal
abscess (1), transitional cell carcinoma (1). Four were males
and one was female.
Adult human tissue other than kidney was either gathered
from storage (formalin-fixed paraffin-embedded) or obtained
fresh from surgical resection within the Department of Histopa-
thology at FMC.
To assess the influence of the time tissues spend in fixative on
the quantification of subsequent positive staining, adjacent
tissue blocks from a single kidney were fixed in 10% formalin
for two hours 48 minutes, 4, 6, 8, 12, 18, 24, 36, and 48 hours,
prior to standardized processing that occurred with all speci-
mens (viz Hypercenter® Tissue Processor, Shandon Scientific,
Cheshire, England).
Immunohistochemistry
Five micrometer frozen sections were cut using a cryotome
(Tissue-Tek II microtome 4451, Miles Laboratories, Illinois,
USA), placed on chrome-alum gelatin coated slides, air dried
and washed in Tris (Analar, BDH Chemicals, Vic 3137, Aus-
tralia) buffered saline, pH 7.6 (TBS) prior to immuno-staining.
Five micrometer paraffin sections were cut using a standard
microtome (Anglia Scientific, Type 300 Cambridge, UK),
placed on acid cleaned glass slides, deparaffinized in xylene and
passed through graded alcohol before placing in TBS prior to
immuno-staining.
To evaluate the effect of protein digestion on immuno-
staining, a series of formalin-fixed paraffin-embedded sections
was placed on acid cleaned glass slides and incubated in a
solution of 0.1% trypsin in 0.1% CaCl2, (pH 7.8) at 37°C for 20
minutes, before being washed in TBS prior to immuno-staining.
Endogenous peroxidase activity was blocked by incubating
sections for 10 minutes in a solution of 0.1% H202 in 100%
ethanol.
Each primary antibody (Ab) was diluted in the normal serum
of the species used to generate the secondary Ab, and the
sections incubated in a humid chamber overnight at 4°C. All
subsequent incubations were performed at room temperature.
The anti-CMP Ab was routinely diluted 1:400, and the anti-
EMA Ab 1:1000.
For single staining, the avidin-biotin immunoperoxidase tech-
nique was used as previously described by Hsu, Raine and
Fanger [14] using a Vectastain® ABC Kit (Vector Laboratories,
Burlingame, California, USA). 3: 3-diaminobenzidine (DAB;
Sigma Chemical Co, St Louis, Missouri, USA) was the chro-
mogen (1.7 x l0— M/liter) used in the presence of 0.024%
hydrogen peroxide to give a brown insoluble precipitate which
was stopped with water after three minutes. Sections were
counterstained in Mayer's hematoxylin, acid differentiated,
blued in lithium carbonate, dehydrated, and mounted in PIX.
Several sections were treated with periodic acid Schiff (PAS)
reagent prior to counterstaining.
Sections were double labeled using a combination of the
immunoperoxidase described above with an alkaline phos-
phatase method. The immunoperoxidase/DAB technique was
used first since it was observed that this relatively insoluble
product was less likely to diffuse during subsequent incubations
than the water soluble alkaline phosphatase/fast red combina-
tion. So, after immunolabeling as detailed above, the tissue was
incubated with the second primary Ab overnight. After incuba-
tion with the second biotinylated linking Ab directed against the
second primary Ab, 0.5% streptavidin alkaline phosphatase
(Biogenex Laboratories, San Ramon, California, USA) was
applied for 30 minutes. Naphthol AS-TR phosphate (Sigma
Chemical Co.) was dissolved in dimethylformamide and added
to Gomari's buffer (pH 9.8) containing 0.03% levamisol. The
chromogen, Fast Red TR Salt (Fl500, Sigma Chemical Co.),
was added to give a characteristic red reaction which was
stopped after 10 minutes by adding excess water. Sections
stained by this method were subsequently air dried and
mounted in Locktite® (Locktite, UK Cat No. 35768, Ireland)
which was polymerized under ultraviolet light for 15 minutes.
Between each of the incubation steps sections were washed
three times in TBS for five minutes.
Light microscopy was performed using a Leitz Wetzler
Diaplan microscope and photography using a Wild MPS 45
camera system with Kodak 35 mm SOASA professional color
film.
Controls
All sections were run in parallel with a negative control of
pre-immune rabbit serum (diluted 1:400) for the anti-CMP
antibody, and TBS for the anti-EMA Ab. Each batch was
accompanied by at least one renal section that had been found
consistently to be positive for CMP.
The anti-CMP Ab was assessed by an affinity-absorption test,
whereby aliquots of CMP, purified by gel filtration and noted to
display a single band on SDS-PAGE, were incubated with the
Ab for two hours at 37°C, and overnight at 4°C. Maximum
"'A -'
dc.t
glom
d
r
I? •; a
-
'- a_-•
: :,
• V
.1
• S
YY
S
— 0 a 14
I'
.4
5'-
a'
e
•0
I
•' glom
—
••
thinlh,
- - -
";talh
9 'a —
—
I'.
-IS
I
-a
820 Stapleton et a!: Distribution of CMP
Fig. 2. Photomicrographs (a), (b), (d) and (e) show sections of human kidney labeled immunohistochemically with anti-human crystal matrix
protein antibody detected with diaminobenzidine to give the brown color. The blue nuclear counterstain is hematoxylin; (a) cortex, intensity of
staining 3+, magnification 560x, (b) cortex counterstained with periodic-acid-Schiff reagent to highlight the carbohydrate moieties, particularly on
the brush border of the proximal convoluted tubular epithelia and absent from the distal tubular epithelia, magnification 560x; (d) outer medulla,
intensity of staining 2+, magnification 900x, (e) cortex showing the macula densa cytoplasm stained positively for crystal matrix protein,
magnification I l25x. Photomicrographs (c) and (f) show sections of human kidney double-labeled immunohistochemically with anti-human crystal
matrix protein antibody detected with Fast Red and anti-human epitheliai membrane antigen detected with diaminobenzidine shown as brown. The
blue nuclear counterstain is haematoxylin; (c) periglomerular tubules of the renal cortex showing crystal matrix protein in the cytoplasm of cells
positive for epithelial membrane antigen, a marker of the distal convoluted tubule, magnification 900x, (0 outer medulla showing crystal matrix
protein (red) in the cytoplasm of tubular epithelia of the TALH with the brown stain corresponding to epithelial membrane antigen, a marker for
the collecting ducts. Red blood cells can be seen in the vasa recta of the medulla, magnification 900x. Abbreviations are: dct, distal convoluted
tubule; talh, thick ascending limb of the loop of Henle; cd, collecting duct; glom, glomerulus; vr, vasa recta; md, macula densa; lh, loop of Henle,
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concentrations of CMP were estimated to be in excess of the
anti-CMP Ab by a factor of 50 to bOx. The samples were then
centrifuged at 3000 rpm for 15 minutes (Labofuge M) and the
supernatant applied to known positive renal tissue and pro-
cessed as described above, using the indirect immunoperoxi-
dase method. Included in this batch was a section incubated
with an appropriately diluted sample of anti-CMP Ab without
added antigen, to act as the positive control.
Quantification of CMP
A separate batch of formalin-fixed paraffin-embcdded tissue
sections was treated in a standard fashion by single labeling
with anti-CMP Ab, keeping uniform the incubation times,
washing, development, etc.
Subjective quantification of intracellular CMP was performed
independently by two of the authors (AMFS and AES) exam-
ining single immunoperoxidase labeled sections using a direct
visual analogue system from 0 (absence of staining), through
1+, 2+, 3+, to 4+ (indicating heavy staining). Each final score
represents the sum of assessments of the DCT and the TALH.
Forty-five kidneys were assessed and the data analyzed using
the Wilcoxon rank sum test, to allow comparison between men
and women, and between healthy subjects and CaOx stone
formers.
Results
Specificity of the anti-CMP antibody
Immunoabsorption using human serum had no perceptible
effect on the titer of the CMP antiserum but the specificity of the
antiserum was enhanced. Figure 1 illustrates that despite the
many proteins in urine only a few are incorporated in CaOx
crystals, the most prominent being at 31 kDa, which has been
called CMP [8]. CMP was detected by the antibody in the urine
sample and in the crystal matrix extract, and was absent from
serum using this technique of Western blotting. There were
reactivities in the extract with molecular weights in excess of 31
kDa. Affinity chromatography, using CMP isolated by prepar-
ative SDS-PAGE, demonstrated these reactivities principally to
be conglomerates of CMP. The antiserum exhibited no cross-
reactivity with urinary THG.
Controls
The sections incubated with rabbit pre-immune serum which
were used as negative controls in each batch were consistently
unstained, unless endogenous peroxidase activity was incom-
pletely quenched. Absorption of the anti-CMP Ab to purified
antigen eliminated labeling—as would be expected with an Ab
of high specificity.
Immunohistochemistry
At appropriate Ab dilutions background staining was low,
and the signal high. Staining for CMP was evident in all but one
of the kidney specimens (98%). The typical staining pattern
seen in the cortex is shown in Figure 2a, which is an example of
indirect immunoperoxidase labeling with DAB, and the nuclei
stained blue with hematoxylin. On the basis of morphological
criteria, such as the relatively tall and cuboidal cell shape [15],
the punctate stain is evident in the distal convoluted tubule
(DCI), and absent from the proximal tubular epithelium, gb-
merulus, and the interstitium. Figure 2b shows a similar pen-
Fig. 3. The intracellular amount of crystal matrix protein (CMP) in the
kidneys of normal men, women, and CaOx stone formers. There is
more CMP in stone formers' kidneys compared with those from either
normal men or normal women (P < 0.01). The difference between
normal men and normal women failed to reach significance (P = 0.11).
gbomerular portion of renal cortex. However, in this section the
counterstain includes PAS, which stains carbohydrate moieties
pink, and highlights the brush borders of the proximal tubular
epithelium which are known to be absent from the distal tubular
epithelium [15]. CMP is confirmed to be within the cytoplasm of
distal tubular epithelial cells.
These findings were consolidated by the double labeling
studies. EMA was noted to be distributed along the apical
membranes of the distal convoluted tubule and collecting duct
epithelia and absent from the glomeruli, proximal tubules, and
the thick and thin limbs of the loops of Henle, as previously
reported [16—19]. Figure 2c shows co-localization of CMP (red)
and EMA (brown) within periglomerular tubular cells consis-
tent with the DCT.
The distribution of CMP in the TALH is demonstrated in
Figure 2d which shows the typical appearance of CMP labeled
by the indirect immunoperoxidase method using DAB. On the
basis of morphological criteria this brown stain is in a cortical
TALH, and the tubule immediately below this is a collecting
duct (CD), which is negative for CMP. Double labeling with
anti-EMA Ab lends support to these findings. Figure 2f is an
example of the double staining technique with the brown DAB
label attached to EMA on the collecting duct epithelia, and the
red stain precipitated to CMP using the alkaline phosphatase
reaction. Clearly, they are in different parts of the nephron;
CMP is in the medullary TALH [15] (note the greater cell height
here compared to the cortical segment of TALH as shown in
Fig. 2d) and the tubule without label above this by comparison
is a thin limb of the loop of Henle. Red blood cells are visible in
the vasa recta (VR), remaining lightly stained by the peroxidase
reaction, despite pretreatment with hydrogen peroxide to re-
duce endogenous peroxidase activity.
Interestingly, CMP was not detected in all nephrons. In fact
staining was heterogeneous amongst the nephron population,
such that in any one individual, between 10% and 60% of the
nephrons were positive. The proportion of positively stained
nephrons was not changed by manipulating the conditions for
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Table 1. Comparison of macromolecular inhibitors of calcium oxalate crystallization
Molecular
weight kDa
Distribution in
the nephron Contains Gla
Inhibitory activity
demonstrated in
Tamm-Horsfall 90 [37, 38] TALH (MD —ye) early No [39] urine 128]
glycoprotein DCT [31, 29]
Nephrocalcin 14 [32] PT, TALH [331 Yes [40] inorganicsolutionst4o]
Uropontin (mice) 55 [341 PT, TALH [34] No [34] inorganicsolutions[34]
Osteopontin (human) 41.5 ;75 [44, 45] DT, CD [36] No [46]
Crystal matrix protein 3118] TALH, DCT (MD +ve) Yes [41] urine [42]
immuno-labeling, such as Ab dilution, formalin fixation time,
time of development of the end product, etc. No one group,
such as cortical or juxtamedullary nephrons, was consistently
stained. Material within the lumina distal to the TALH was also
noted to be positive for CMP, as one would expect with release
of CMP into the urinary space. CMP was consistently demon-
strated in the cells of the macula densa in those nephrons that
were positively stained elsewhere (Fig. 2e).
The different methods of initial tissue processing did not alter
the specific distribution of CMP within the kidney, although
background staining was increased in tissue fixed in Zamboni's
solution or snap frozen in liquid nitrogen.
Trypsinization of the archival sections did not influence the
sites or the intensity of positive staining, indicating that the
CMP antigen is not masked by protein cross-linking during
fixation or processing of tissue in 10% formalin, 2.5% glut-
araldahyde, or paraffin wax embedding.
CMP was not detected despite using varying Ab dilutions, in
27 separate human organs: renal pelvis, ureter, bladder, pros-
tate, testis, epididymis, lung, liver, spleen, pancreas, oesopha-
gus, stomach, jejunum, ileum, colon, skeletal muscle, smooth
muscle, heart, skin, thyroid, parathyroid, bone marrow, tonsil,
adrenal, uterus, breast, cerebral cortex. It is noteworthy that
within the urinary system the kidney was the only tissue to stain
positively for CMP.
Quantification of CMP in renal tissue
The intensity of staining of CMP evident after tissue had been
fixed in formalin for between two hours 48 minutes, and 48
hours showed no variation. Staining intensity was equal be-
tween the TALH and the DCT in 19 cases (42%), the TALH
stained more than the DCT in nine cases (20%) and in the
remaining 17 cases (38%) the DCT showed greater intensity of
staining for CMP than the TALH. The mean scores for each
group were: (1) normal males, TALH 1,7, DCT 1.8, (2)
normal females, TALH = 1.2, DCT = 1.5, and (3) stone
formers, TALH 2.8, DCT 3.8.
The combined histological quantification data are illustrated
in Figure 3. Significantly less CMP was observed in normal
women compared with stone formers (P < 0.01), and there was
less CMP in normal men compared with stone formers (P <
0.01). The difference in the amount of CMP detected in kidneys
from normal males, as opposed to normal females, failed to
reach statistical significance (P = 0.11), although the trend
suggested the occurrence of less CMP in the latter.
Discussion
The consistent presence and disproportionate abundance of
CMP within the structure of CaOx crystals generated from
human urine suggest that the protein may fulfill an active role in
CaOx crystallization, and perhaps, therefore, in CaOx stone
disease. Using a polyclonal antibody of high specificity we have
demonstrated the presence of CMP in the tubular epithelia of
the TALH and the DCT of the human kidney. Its precise
location in these structures was confirmed by simultaneous
staining for EMA, which is known to be confined to the distal
convoluted tubules and collecting ducts. CMP was also clearly
seen within the cells of the macula densa, but whether it
contributes to the function of this complex is not known. The
definite location of CMP within the lumen adjacent and distal to
these sites suggests that the protein is produced by and secreted
from these cells into the urinary collecting system. Further-
more, the protein appears to be specific to the kidney, with
none being detected elsewhere in the urinary tract or in other
human tissues.
This very limited and precise location, both within the body
and the kidney, lends credence to the possibility that it may
fulfil some regulatory role in stone pathogenesis. The DCT has
a large capacity for calcium absorption, reclaiming as much as
90% of the load presented to it [24], and this transport is active.
Transport of calcium also occurs against an electrochemical
gradient in the connecting tubule where vitamin D-stimulated
calcium-binding protein is present [25]. Some authors have
postulated that this portion of the nephron may be the control
point for calcium excretion [26]. Given therefore that calcium
transport is significantly controlled in this section and that
luminal fluid is progressively concentrated dependent upon
hydration both here and distally, calcium and oxalate concen-
trations may be maximal in the collecting ducts. It is notewor-
thy that histological studies of human kidneys have shown
calcium mineral deposits in collecting ducts, but not in the more
proximal nephron [27]. Therefore, it would be physiologically
advantageous to minimize the risk of crystal precipitation in the
collecting ducts by releasing an inhibitor of CaOx crystalliza-
tion into the luminal fluid immediately upstream in the nephron.
Nonetheless, although CMP would appear to fulfill both the
anatomical and physicochemical criteria of a critical macromo-
lecular determinant of CaOx stone disease, other urinary pro-
teins can also claim such distinction, and it is salient to compare
their properties with those of CMP.
Tamm-Horsfall glycoprotein (THG) is a potent inhibitor of
CaOx crystallization in human urine at normal urine osmolality
[28] and is localized to the distal tubule of the nephron [29—311.
Using a fully characterized monoclonal antibody, studies of its
ultrastructural distribution showed that in the DCT, only the
luminal plasmalemma is positive while the basolateral mem-
branes and the cytoplasm are negative. In the epithelial cells of
the TALH, on the other hand, THG is distributed throughout
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the whole cell plasmalemma [291. Our light microscopic findings
of more centrally placed punctate staining for CMP within the
cells of both of these segments demonstrate that the distribution
of CMP is different from that of THG. This is supported by our
finding that the cells of the macula densa contain CMP and are
negative for THG [29]. It is apparent, therefore, that THG and
CMP are distinct proteins and, if they are both involved in stone
pathogenesis, their roles are unlikely to coincide.
Nephrocalcin (NC) is a 14 kDa glycoprotein which has been
reported to inhibit CaOx crystal growth in inorganic solutions,
but whose effects in undiluted urine have not been tested [32].
Using a rabbit polyclonal Ab, NC has been shown by Naka-
gawa and his colleagues to be present in the proximal tubules
and the TALH epithelia of both human and mouse kidneys [33].
These authors have therefore proposed that NC protects
against CaOx crystallization at two different sites within the
nephron. The dissimilar distributions of CMP and NC within
the nephron, and the disparity in their molecular weights
suggests that they are different proteins and probably fulfill
different functions.
More recently, another potentially important urinary protein
has been described. Shiraga et al [34] isolated an aspartate-rich
protein from urine, which they named uropontin, and showed to
be an inhibitor of CaOx crystal growth in inorganic solutions.
There is indirect evidence that it is synthesized by cells in the
proximal and distal tubules and loops of Henle in mice. Given
that there is significant sequence homology between uropontin
and osteopontin [34], osteopontin's presence is implied in these
areas by the detection of transcripts by Northern analysis using
labeled probes encoding osteopontin [35]. Using immunohisto-
chemistry and in situ hybridization, Brown et al [36] found
osteopontin to be present in the distal tubules and collecting
ducts of the human kidney, and also in the transitional epithe-
hum of the renal pelvis and focally in the bladder. Uropontin
has a molecular weight of 55 kDa and amino acid analysis
reveals an absence of Gla [34], features that clearly distinguish
it from CMP. The characteristics of these four known macro-
molecular inhibitors of calcium oxalate crystallization are sum-
marized in Table 1.
If CMP is indeed a distinct urinary protein which fulfills some
regulatory function in stone pathogenesis, we may reasonably
expect that its quantity in kidneys from stone formers would
differ from that in individuals who have never suffered from
urolithiasis. Furthermore, since the incidence of calculi is some
three times higher in men than women [43], this difference
should be reflected in disparities between the amounts of the
protein detected in the kidney tissue of the two sexes. CMP was
detected in significantly greater amounts in sections of kidneys
from stone formers than in those from individuals unaffected by
the disease, and though the difference failed to attain statistical
significance, the data also demonstrated a trend for normal
males to have greater quantities of CMP than normal females.
The observed quantity of CMP therefore mirrors the risk of
stone disease, such that an increased amount of CMP correlates
with an increased incidence of stone disease. These data appear
to conflict with the fact that CMP is a potent inhibitor of CaOx
crystal aggregation, where one might expect a greater risk of
stone disease to result from a decreased level of urinary
inhibitors. A number of explanations can be proposed for this
apparent contradiction, including differences in molecular
structure (and therefore functional activity), stimulation of the
protein's production and secretion under conditions of high
urinary supersaturation, and alterations in the transport mech-
anisms required to deliver the protein into the lumen.
In summary, this study has demonstrated the distribution of
a newly described urinary protein, crystal matrix protein,
within the TALH and the DCT of the human nephron, and its
absence from other areas of the kidney and many other organs.
The precise, limited distribution of CMP and its inhibitory
effects on CaOx crystal growth and aggregation strongly sug-
gest that it may play a pivotal role in stone matrix deposition,
and further studies are clearly warranted to clarify its role in
stone pathogenesis.
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Note added in proof
Since submission of this paper, the authors have shown that CMP is
related to human prothrombin. Further analysis indicates that our
anti-CMP antibody does stain the cytoplasm of hepatocytes, albeit with
quite different characteristics than are observed in the kidney.
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